TMDI - TMDI STOCK NEWS

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) announced that President and CEO David McNally will present an overview of the company and its Enos™ robotic surgical system at the Oppenheimer MedTech Summit Investor Conference on May 26, 2021, at 8:00 a.m. ET. The presentation link will be available on Titan's website. The Enos system aims to enhance robotic assisted surgery with ergonomic technology and multi-articulating instruments, focusing initially on gynecologic surgical indications. Titan has licensed certain technologies to Medtronic while retaining worldwide commercialization rights for Enos.

Titan Medical Inc. (Nasdaq: TMDI) announced financial results for Q1 2021, reporting a cash position of $53.4 million and a net loss of $14.8 million. The substantial increase in loss is attributed to rising research and development expenses of $7.6 million, primarily for the Enos™ robotic surgical system. Significant progress includes raising $34.5 million through equity financings. The company appointed Paul Cataford as Chairman and welcomes Heather Knight and Cathy Steiner to the board. Titan aims to enhance robotic-assisted surgery focusing on gynecologic indications and is on track to meet FDA expectations for clinical studies planned in 2022.

Titan Medical Inc. (TMDI) plans to release its first quarter financial results on May 17, 2021. Following the announcement, the management team will host an investor audio webcast at 4:30 p.m. ET, featuring key executives discussing performance and business highlights. Titan is focused on developing robotic-assisted surgical technologies, particularly the Enos™ system for gynecologic surgery. The company retains worldwide commercialization rights despite licensing some technologies to Medtronic plc.

Titan Medical announced the appointment of Kristen Galfetti as Vice President of Investor Relations & Corporate Communications and Chien Huang as Vice President Finance. Galfetti, with over 20 years of experience, previously served at Cynapsus Therapeutics and Sanofi. Huang brings extensive financial expertise, having worked at Quarterhill Inc. and Aralez Pharmaceuticals. This leadership expansion aims to enhance Titan's growth as it moves towards human clinical studies for its Enos™ robotic surgical system, which focuses on gynecologic surgeries.

Titan Medical Inc. (TMDI) announced that David McNally, President and CEO, will present the Enos™ robotic surgical system at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2021, at 2:00 p.m. ET. The presentation will provide insights into Titan's focus on developing robotic technologies for single access surgery, particularly in gynecology. The Enos system features dual 3D and 2D vision and multi-articulating instruments. Titan has licensed certain technologies to Medtronic but retains rights for its Enos system.

Titan Medical Inc. (TMD, TMDI) announced that its President and CEO David McNally, along with CFO Monique Delorme, will participate in two virtual investor conferences. On March 16, 2021, Titan will host one-on-one investor meetings at the 33rd Annual ROTH Conference. Following that, on March 17, 2021, at 2:30 p.m. ET, the company will join a fireside chat to discuss its Enos™ robotic single access surgical system during the Oppenheimer 31st Annual Healthcare Conference. Interested parties can access the events through the company’s website.

Titan Medical Inc. (TMD, TMDI) has announced a corporate update during the H.C. Wainwright Global Life Sciences Conference, highlighting its Enos™ robotic single access surgical system. The system aims to reduce trauma and enhance recovery in gynecologic surgeries, tapping into a potential $18 billion U.S. surgical robotics market. Titan's strong cash position of approximately $65.5 million supports its aggressive development timeline, with plans for a clinical study in 2022 and expected additional license revenue of $21 million in 2021 from its partnership with Medtronic.

Titan Medical Inc. (TSX: TMD, Nasdaq: TMDI) has successfully closed its offering of 8,335,000 units, yielding gross proceeds of $20,004,000. An additional 1,250,250 units were sold due to over-allotment, bringing total gross proceeds to $23,004,600. Each unit consists of one common share and one-half warrant, with full warrants priced at $3.00 until February 24, 2023. Proceeds will fund the development of robotic surgical technologies and support general working capital.

Titan Medical Inc. (TMD, TMDI) reported a significant year in 2020, achieving $20.0 million in revenue primarily through agreements with Medtronic. This included securing roughly $22.0 million from equity financings and a $1.5 million senior loan from Medtronic. Cash reserves improved to approximately $25.5 million by year-end 2020, up from $0.8 million in 2019. The company plans to commence human clinical studies for its Enos™ robotic system and expects to raise an additional $20.0 million in financing soon.